

CITATION REPORT

List of articles citing

Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis

DOI: 10.1002/ajh.25308

American Journal of Hematology, 2019, 94, 55-61.

Source: <https://exaly.com/paper-pdf/74809473/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
60	New and emerging treatments for vaso-occlusive pain in sickle cell disease. <i>Expert Review of Hematology</i> , 2019 , 12, 857-872	2.8	4
59	"Stuck on sugars - how carbohydrates regulate cell adhesion, recognition, and signaling". <i>Glycoconjugate Journal</i> , 2019 , 36, 241-257	3	5 ¹
58	Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease. <i>Pharmacotherapy</i> , 2019 , 39, 1095-1104	5.8	13
57	Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date. <i>Journal of Blood Medicine</i> , 2019 , 10, 307-311	2.3	7
56	Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target?. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 819-828	6.4	24
55	Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease. <i>Experimental Biology and Medicine</i> , 2019 , 244, 171-182	3.7	8
54	Pain and sickle cell disease. <i>Current Opinion in Hematology</i> , 2019 , 26, 131-138	3.3	9
53	Antibodies to watch in 2019. <i>MAbs</i> , 2019 , 11, 219-238	6.6	323
52	Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 140-146	6.1	3
51	Treating sickle cell anemia: A new era dawns. <i>American Journal of Hematology</i> , 2020 , 95, 338-342	7.1	10
50	Antibodies to watch in 2020. <i>MAbs</i> , 2020 , 12, 1703531	6.6	269
49	Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease. <i>American Journal of Hematology</i> , 2020 , 95, E338-E339	7.1	5
48	Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. <i>Therapeutic Advances in Hematology</i> , 2020 , 11, 2040620720955000	5.7	7
47	HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation. <i>Blood Advances</i> , 2020 , 4, 4560-4572	7.8	8
46	Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?. <i>Blood Advances</i> , 2020 , 4, 3457-3465	7.8	5
45	Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
44	Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. <i>Experimental Hematology</i> , 2020 , 92, 11-18.e1	3.1	12

43	The molecular basis for the prothrombotic state in sickle cell disease. <i>Haematologica</i> , 2020 , 105, 2368-2379	12
42	Crizanlizumab. <i>Hospital Pharmacy</i> , 2020 , 001857872092537	1.1 1
41	Advances in Sickle Cell Disease Management. <i>Advances in Pediatrics</i> , 2020 , 67, 57-71	2.2 3
40	Recent Advances in the Treatment of Sickle Cell Disease. <i>Frontiers in Physiology</i> , 2020 , 11, 435	4.6 40
39	Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment. <i>Blood Cells, Molecules, and Diseases</i> , 2020 , 83, 102424	2.1 17
38	Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review. <i>Frontiers in Pediatrics</i> , 2020 , 8, 38	3.4 22
37	Crizanlizumab: First Approval. <i>Drugs</i> , 2020 , 80, 79-84	12.1 18
36	Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. <i>Pharmacotherapy</i> , 2020 , 40, 535-543	5.8 8
35	The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. <i>European Journal of Haematology</i> , 2020 , 105, 237-246	3.8 33
34	Novel antiplatelet targets in the treatment of acute coronary syndromes. <i>Platelets</i> , 2021 , 32, 15-28	3.6 7
33	The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease. <i>Frontiers in Immunology</i> , 2020 , 11, 561917	8.4 15
32	The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 217-243	64.1 60
31	Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials. <i>PLoS ONE</i> , 2021 , 16, e0246700	3.7 2
30	P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab. <i>Journal of Pain Research</i> , 2021 , 14, 849-856	2.9 6
29	Microfluidics in Sickle Cell Disease Research: State of the Art and a Perspective Beyond the Flow Problem. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 558982	5.6 2
28	Cardiac pathophysiology in sickle cell disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 248-259	5.1 1
27	Advances in Sickle Cell Disease Treatments. <i>Current Medicinal Chemistry</i> , 2021 , 28, 2008-2032	4.3 3
26	Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease. <i>Journal of Pharmacy Technology</i> , 2021 , 37, 209-215	0.6 1

25	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. <i>Blood Advances</i> , 2021 , 5, 2403-2411	7.8	6
24	Research in Sickle Cell Disease: From Bedside to Bench to Bedside. <i>HemaSphere</i> , 2021 , 5, e584	0.3	5
23	Pain in sickle cell disease: current and potential translational therapies. <i>Translational Research</i> , 2021 , 234, 141-158	11	0
22	Management of refractory chronic pain in sickle cell disease with intrathecal drug delivery system. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 ,	1.6	
21	Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease. <i>British Journal of Haematology</i> , 2021 , 194, 1074-1082	4.5	1
20	Sickle cell disease: progress towards combination drug therapy. <i>British Journal of Haematology</i> , 2021 , 194, 240-251	4.5	4
19	Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study. <i>Journal of Health Economics and Outcomes Research</i> , 2020 , 7, 52-60	1.6	7
18	Sickle cell disease. 2020 , 595-609		
17	Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.. <i>Journal of Oncology Pharmacy Practice</i> , 2022 , 10781552211072468	1.7	
16	A critical evaluation of crizanlizumab for the treatment of sickle cell disease.. <i>Expert Review of Hematology</i> , 2021 , 1-9	2.8	0
15	High-Throughput Assay to Screen Small Molecules for Their Ability to Prevent Sickling of Red Blood Cells.. <i>ACS Omega</i> , 2022 , 7, 14009-14016	3.9	0
14	Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases. <i>Heliyon</i> , 2022 , 8, e09630	3.6	
13	The oral ferroportin inhibitor vamifeport improved hemodynamics in a mouse model of sickle cell disease. <i>Blood</i> ,	2.2	3
12	Sickle Cell Disease. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 328, 57	27.4	5
11	Novel Strategies for the Treatment of COVID-19.		2
10	Hemoglobinopathies and Thalassemias. 2023 , 143-172		
9	Diverse Approaches to Gene Therapy of Sickle Cell Disease. 2023 , 74,		0
8	Under the hood: The molecular biology driving gene therapy for the treatment of sickle cell disease. 2022 , 103566		0

- 7 Sickle cell disease in the new era: Advances in drug treatment. **2022**, 103555 ○
- 6 Hydroxyurea (hydroxycarbamide) for sickle cell disease. **2022**, 2022, 3
- 5 Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine. **2022**, 10, 123 ○
- 4 Adhesion molecules and cerebral microvascular hemodynamic abnormalities in sickle cell disease. 13, ○
- 3 Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease. ○
- 2 Evidence-Based Minireview: How to utilize new therapies for sickle cell disease. **2022**, 2022, 283-285 ○
- 1 Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies. **2023**, 40, 317-334 ○